EX-99 2 exhibit_1.htm PRESS RELEASE
Exhibit 1


For Immediate Release

BioLineRx Reports Year-End 2019 Financial Results
and Provides Corporate Update

- On track to report progression free survival and overall survival data from triple
combination arm of ongoing COMBAT/KEYNOTE-202 Phase 2a trial in mid-2020 -

- Management to hold conference call today,
March 12, at 10:00 am EDT -

TEL AVIV, Israel, March 12, 2020 -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the year ended December 31, 2019 and provides a corporate update.

Highlights and achievements during the fourth quarter 2019 and subsequent period:


 •
Presented updated preliminary Phase 2a data from the triple combination arm of the COMBAT/KEYNOTE-202 study, under collaboration with Merck, evaluating the safety, tolerability and efficacy of motixafortide (BL-8040) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy in patients with second-line metastatic pancreatic cancer, demonstrating a 32% overall response rate and a 77% disease control rate out of 22 evaluable patients at that time, with median duration of clinical benefit for all 17 patients with disease control (7 partial response and 10 stable disease patients) of 7.8 months; and reiterated expectation for progression free survival and overall survival data in mid-2020;


•
Completed recruitment (N=43) of the triple combination arm of the COMBAT/KEYNOTE-202 study;


•
Announced Notice of Allowance from USPTO for a broad patent covering motixafortide in combination with anti-PD-1 for the treatment of any and all types of cancer;


•
Received Orphan Drug Designation for motixafortide for the treatment of pancreatic cancer in Europe;


•
Presented positive triple-combination preclinical data from the evaluation of motixafortide in combination with an anti-PD-1 and chemotherapy in pancreatic cancer, supporting motixafortide’s mechanism of action and providing additional strong rationale for the triple-combination clinical study, at the Society for Immunotherapy of Cancer Annual Meeting (SITC).

“We achieved a significant milestone during the fourth quarter of 2019 with the announcement of preliminary data from the ongoing triple combination arm of our COMBAT/KEYNOTE-202 study in second-line pancreatic cancer,” stated Philip Serlin, Chief Executive Officer of BioLineRx. “The promising initial results demonstrated robust and durable responses to the triple combination treatment, with an overall response rate almost double the current chemotherapy standard-of-care treatment in second-line patients, and a trend of patients receiving treatment for an extended period that move from stable disease to partial response. Looking ahead, we have now fully enrolled this study and remain on track to announce progression free and overall survival data in mid-year.

“In parallel, our late-stage trials of motixafortide in AML and stem cell mobilization are progressing, and we also look forward to these key data readouts later this year.

“Regarding our second clinical oncology candidate, the universal anti-cancer vaccine AGI-134, we successfully completed the dose-escalation Part 1 of the ongoing Phase 1/2a clinical trial in a range of solid tumor types, and are currently advancing Part 2 of the study as expeditiously as possible. We look forward to initial results of Part 2 by year-end 2020,” Mr. Serlin concluded.

Upcoming 2020 Milestones


 •
Progression-free survival and overall survival data from the triple combination arm of the COMBAT/KEYNOTE-202 Phase 2a study in mid-2020;


•
Interim results from the Phase 2b AML consolidation study in the second half of 2020;

2

 •
Top-line results from Phase 3 GENESIS registrational study in stem cell mobilization in the second half of 2020;


•
Initial results from Part 2 of Phase 1/2a trial of AGI-134 by year-end 2020.

Financial Results for the Year Ended December 31, 2019

Research and development expenses for the year ended December 31, 2019 were $23.4 million, an increase of $3.6 million, or 18.3%, compared to $19.8 million for the year ended December 31, 2018. The increase resulted primarily from higher expenses associated with the motixafortide GENESIS and COMBAT clinical trials, offset by a decrease in expenses related to BL-1230, a project that was terminated in 2018, as well as a decrease in payroll and share-based compensation.

Sales and marketing expenses for the year ended December 31, 2019 were $0.9 million, a decrease of $0.5 million, or 37.0%, compared to $1.4 million for the year ended December 31, 2018. The decrease resulted primarily from a decrease in payroll and related expenses, including a one-time compensation payment in the 2018 period.

General and administrative expenses for the year ended December 31, 2019 were $3.8 million, a decrease of $0.6 million, or 14.0% compared to $4.4 million for the year ended December 31, 2018. The decrease resulted primarily from a decrease in share-based compensation.

The Company's operating loss for the year ended December 31, 2019 amounted to $28.1 million, compared to an operating loss of $25.6 million for the year ended December 31, 2018.

Non-operating income amounted to $4.2 million for the year ended December 31, 2019, compared to non-operating income of $2.4 million for the year ended December 31, 2018. Non-operating income for the year ended December 31, 2019 primarily relates to fair-value adjustments of warrant liabilities on the Company’s balance sheet, offset by warrant offering expenses. Non-operating income for the year ended December 31, 2018 primarily relates to fair-value adjustments of warrant liabilities on the Company’s balance sheet, as well as a capital gain from realization of the investment in iPharma.

Net financial expenses amounted to $1.5 million for the year ended December 31, 2019 compared to net financial income of $0.2 million for the year ended December 31, 2018. Net financial expenses for the year ended December 31, 2019 primarily relate to interest paid on loans, offset by investment income earned on bank deposits. Net financial income for the year ended December 31, 2018 primarily relates to investment income earned on bank deposits, offset by interest paid on loans.

3
The Company's net loss for the year ended December 31, 2019 amounted to $25.5 million, compared with a net loss of $23.0 million for the year ended December 31, 2018.

The Company held $27.5 million in cash, cash equivalents and short-term bank deposits as of December 31, 2019.

Net cash used in operating activities for the year ended December 31, 2019 was $22.7 million, compared to $24.2 million for the year ended December 31, 2018. The $1.5 million decrease in net cash used in operating activities in 2019 was primarily the result of changes in operating asset and liability items in the two periods., i.e., a decrease in prepaid expenses and other receivables in 2019 versus an increase in 2018, as well as an increase in accounts payable and accruals in 2019 versus a decrease in 2018.

Net cash provided by investing activities for the year ended December 31, 2019 was $5.3 million, compared to $9.6 million for the year ended December 31, 2018. The changes in cash flows from investing activities relate primarily to investments in, and maturities of, short-term bank deposits during both periods, the acquisition of an additional 20% economic interest in Motixafortide in 2018, as well as a realization of the investment in iPharma during 2018.

Net cash provided by financing activities for the year ended December 31, 2019 was $19.2 million, compared to $13.1 million for the year ended December 31, 2018. The cash flows in 2019 primarily reflect the underwritten public offering of ADSs in February 2019, as well as net proceeds from the ATM program. The cash flows in 2018 reflect the net proceeds of the loan from Kreos Capital, as well as net proceeds from the ATM program.

Conference Call and Webcast Information

BioLineRx will hold a conference call today, March 12, 2020 at 10:00 a.m. EDT. To access the conference call, please dial +1-888-668-9141 from the US or +972-3-918-0609 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx’s website. A dial-in replay of the call will be available until March 14, 2020; please dial +1-877-456-0009 from the US or +972-3-925-5927 internationally.

(Tables follow)

4
About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company’s lead program, motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA® and chemotherapy under a collaboration agreement with MSD. Motixafortide is also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company’s website at www.biolinerx.com, where you can review the Company’s SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Various statements in this release concerning BioLineRx’s future expectations constitute "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may,” "expects,” "anticipates,” "believes,” and "intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2020. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:
Tim McCarthy
LifeSci Advisors, LLC
+1-212-915-2564
tim@lifesciadvisors.com

or

Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com
 
5
BioLineRx Ltd.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
             
   
December 31,
  
   
2018
    
2019
  
   
in USD thousands
  
Assets
            
CURRENT ASSETS
            
Cash and cash equivalents
    
3,404
      
5,297
  
Short-term bank deposits
    
26,747
      
22,192
  
Prepaid expenses
    
488
      
108
  
Other receivables
    
1,339
      
613
  
Total current assets
    
31,978
      
28,210
  
                 
NON-CURRENT ASSETS
                
Long-term prepaid expenses
    
56
      
-
  
Property and equipment, net
    
2,227
      
1,816
  
Right-of-use assets, net
    
-
      
1,650
  
Intangible assets, net
    
21,972
      
21,891
  
Total non-current assets
    
24,255
      
25,357
  
Total assets
    
56,233
      
53,567
  
                 
Liabilities and equity
                
CURRENT LIABILITIES
                
Current maturities of long-term loans
    
895
      
2,692
  
Accounts payable and accruals:
                
Trade
    
4,493
      
7,794
  
Other
    
1,363
      
1,280
  
Lease liabilities
    
-
      
202
  
Total current liabilities
    
6,751
      
11,968
  
                 
NON-CURRENT LIABILITIES
                
Warrants
    
323
      
658
  
Long-term loans, net of current maturities
    
7,838
      
5,799
  
Lease liabilities
    
-
      
1,762
  
Total non-current liabilities
    
8,161
      
8,219
  
                 
COMMITMENTS AND CONTINGENT LIABILITIES
                
Total liabilities
    
14,912
      
20,187
  
                 
EQUITY
                
Ordinary shares
    
3,110
      
4,692
  
Share premium
    
250,192
      
265,938
  
Capital reserve
    
11,955
      
12,132
  
Other comprehensive loss
    
(1,416
)
    
(1,416
)
Accumulated deficit
    
(222,520
)
    
(247,966
)
Total equity
    
41,321
      
33,380
  
Total liabilities and equity
    
56,233
      
53,567
  
 
6
BioLineRx Ltd.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
 
   
Year ended December 31,
  
   
2017
    
2018
    
2019
  
   
in USD thousands
  
                   
RESEARCH AND DEVELOPMENT EXPENSES
    
(19,510
)
    
(19,808
)
    
(23,438
)
SALES AND MARKETING EXPENSES
    
(1,693
)
    
(1,362
)
    
(857
)
GENERAL AND ADMINISTRATIVE EXPENSES
    
(4,037
)
    
(4,435
)
    
(3,816
)
OPERATING LOSS
    
(25,240
)
    
(25,605
)
    
(28,111
)
NON-OPERATING INCOME (EXPENSES), NET
    
(260
)
    
2,397
      
4,165
  
FINANCIAL INCOME
    
1,169
      
719
      
777
  
FINANCIAL EXPENSES
    
(21
)
    
(473
)
    
(2,277
)
NET LOSS AND COMPREHENSIVE LOSS
    
(24,352
)
    
(22,962
)
    
(25,446
)
                         
   
in USD
  
LOSS PER ORDINARY SHARE – BASIC AND DILUTED
    
(0.27
)
    
(0.21
)
    
(0.17
)
                         
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE
    
89,970,713
      
108,595,702
      
146,407,055
  

7

BioLineRx Ltd.
STATEMENTS OF CHANGES IN EQUITY

   
Ordinary shares
    
Share premium
    
Capital reserve
    
Other comprehensive
loss
    
Accumulated deficit
    
Total
  
   
in USD thousands
  
BALANCE AT JANUARY 1, 2017
    
1,513
      
199,567
      
10,569
      
(1,416
)
    
(175,206
)
    
35,027
  
CHANGES IN 2017:
                                                
  Issuance of share capital, net
    
1,322
      
39,376
      
-
      
-
      
-
      
40,698
  
  Employee stock options exercised
    
1
      
328
      
(329
)
    
-
      
-
      
-
  
  Employee stock options forfeited and expired
    
-
      
1,411
      
(1,411
)
    
-
      
-
      
-
  
  Share-based compensation
    
-
      
-
      
1,508
      
-
      
-
      
1,508
  
  Comprehensive loss for the year
    
-
      
-
      
-
      
-
      
(24,352
)
    
(24,352
)
BALANCE AT DECEMBER 31, 2017
    
2,836
      
240,682
      
10,337
      
(1,416
)
    
(199,558
)
    
52,881
  
CHANGES IN 2018:
                                                
  Issuance of share capital, net
    
263
      
8,567
      
-
      
-
      
-
      
8,830
  
  Employee stock options exercised
    
11
      
415
      
(380
)
    
-
      
-
      
46
  
  Employee stock options forfeited expired
    
-
      
528
      
(528
)
    
-
      
-
      
-
  
  Share-based compensation
    
-
      
-
      
2,526
      
-
      
-
      
2,526
  
  Comprehensive loss for the year
    
-
      
-
      
-
      
-
      
(22,962
)
    
(22,962
)
BALANCE AT DECEMBER 31, 2018
    
3,110
      
250,192
      
11,955
      
(1,416
)
    
(222,520
)
    
41,321
  
CHANGES IN 2019:
                                                
  Issuance of share capital, net
    
1,580
      
14,165
      
-
      
-
      
-
      
15,745
  
  Employee stock options exercised
    
2
      
83
      
(84
)
    
-
      
-
      
1
  
  Employee stock options forfeited and expired
    
-
      
1,498
      
(1,498
)
    
-
      
-
      
-
  
  Share-based compensation
    
-
      
-
      
1,759
      
-
      
-
      
1,759
  
  Comprehensive loss for the year
    
-
      
-
      
-
      
-
      
(25,446
)
    
(25,446
)
BALANCE AT DECEMBER 31, 2019
    
4,692
      
265,938
      
12,132
      
(1,416
)
    
(247,966
)
    
33,380
  

8
BioLineRx Ltd.
CONSOLIDATED CASH FLOW STATEMENTS
 
   
Year ended December 31,
  
   
2017
    
2018
    
2019
  
   
in USD thousands
  
CASH FLOWS - OPERATING ACTIVITIES
                  
Net loss
    
(24,352
)
    
(22,962
)
    
(25,446
)
Adjustments required to reflect net cash used in operating activities (see appendix below)
    
3,805
      
(1,230
)
    
2,780
  
Net cash used in operating activities
    
(20,547
)
    
(24,192
)
    
(22,666
)
                         
CASH FLOWS - INVESTING ACTIVITIES
                        
     Increase in long-term investment
    
(1,000
)
    
-
      
-
  
Realization of long-term investment
    
-
      
1,500
      
-
  
     Investments in short-term deposits
    
(44,016
)
    
(26,500
)
    
(43,545
)
     Maturities of short-term deposits
    
33,327
      
44,771
      
48,875
  
Purchase of property and equipment
    
(338
)
    
(173
)
    
(67
)
Purchase of intangible assets
    
(3,900
)
    
(10,043
)
    
(6
)
Net cash provided by (used in) investing activities
    
(15,927
)
    
9,555
      
5,257
  
                         
CASH FLOWS - FINANCING ACTIVITIES
                        
Issuance of share capital and warrants, net of issuance cost
    
38,773
      
3,830
      
20,297
  
     Employee stock options exercised
    
-
      
46
      
1
  
     Proceeds of long-term loan and warrants, net of issuance costs
    
-
      
9,632
      
-
  
     Repayment of loans
    
(93
)
    
(411
)
    
(889
)
     Repayments of lease liabilities
    
-
      
-
      
(215
)
Net cash provided by financing activities
    
38,680
      
13,097
      
19,194
  
                         
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
    
2,206
      
(1,540
)
    
1,785
  
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR
    
2,469
      
5,110
      
3,404
  
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS
    
435
      
(166
)
    
108
  
CASH AND CASH EQUIVALENTS - END OF YEAR
    
5,110
      
3,404
      
5,297
  

9

BioLineRx Ltd.
CONSOLIDATED CASH FLOW STATEMENTS
 
   
Year ended December 31,
  
   
2017
    
2018
    
2019
  
   
in USD thousands
  
APPENDIX
                  
                   
Adjustments required to reflect net cash used in operating activities:
                  
Income and expenses not involving cash flows:
                  
Depreciation and amortization
    
481
      
545
      
940
  
Long-term prepaid expenses
    
(9
)
    
5
      
56
  
Exchange differences on cash and cash equivalents
    
(435
)
    
166
      
(108
)
Fair value adjustments of warrants
    
127
      
(1,743
)
    
(4,634
)
                         
Share-based compensation
    
1,508
      
2,526
      
1,759
  
Interest and exchange differences on short-term deposits
    
(530
)
    
(645
)
    
(775
)
Interest on loans
    
-
      
123
      
647
  
Gain on realization of long-term investment
    
-
      
(500
)
    
-
  
Warrant issuance costs
    
17
      
-
      
417
  
Exchange differences on lease liability
    
-
      
-
      
154
  
     
1,159
      
477
      
(1,544
)
                         
Changes in operating asset and liability items:
                        
Decrease (increase) in prepaid expenses and other receivables
    
(415
)
    
(934
)
    
1,106
  
Increase (decrease) in accounts payable and accruals
    
3,061
      
(773
)
    
3,218
  
     
2,646
      
(1,707
)
    
4,324
  
                         
     
3,805
      
(1,230
)
    
2,780
  
                         
Supplemental information on interest received in cash
    
494
      
834
      
868
  
                         
Supplemental information on interest paid in cash
    
12
      
165
      
1,198
  
                         
Supplemental information on non-cash transactions
    
2,985
      
5,000
      
147
  

10